A sample of Testosterone Cypionate 300, manufactured by HYB (Yurapeptide), underwent independent testing to verify its potency. The sample was anonymously procured by an individual consumer, Keilani, and the analysis was paid for by the individual. Testing was conducted by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control.
The measured concentration of 286.80 mg/ml was found against a labeled specification of 300 mg/ml, representing an underdosage of 4.4%. While this confirms that the product contains the active ingredient close to the expected potency, it does raise minor concerns about consistency in dosage accuracy.
These findings contribute to harm reduction efforts, ensuring transparency and accurate consumer information regarding the quality of HYB’s Testosterone Cypionate.
Detailed Report
Product Overview
- Manufacturer: HYB (Yurapeptide)
- Product Name: Testosterone Cypionate 300
- Active Ingredient: Testosterone Cypionate
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #57379
- Testing Ordered: 30 January 2025
- Sample Received: 6 February 2025
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Keilani (Individual)
- Analysis Paid For By: Keilani (Individual)
Testing Results
| Component/Test | Specification (Label Claim) | Measured Concentration | Accuracy | Variance |
|---|---|---|---|---|
| Testosterone Cypionate | 300 mg/ml | 286.80 mg/ml | 95.6% | -4.4% |
Verification Details
- Verification URL: https://janoshik.com/tests/57379_SB1K25FLDL9K
- Originally Published: https://thinksteroids.com/community/posts/3438150/
Evaluation of Independent Testing
The test results indicate a measured potency of 95.6% relative to the label claim, with a 4.4% underdosage. While slightly below the labeled claim, this variance is within a reasonable margin for pharmaceutical products. However, consistent underdosage across multiple batches would indicate potential quality control concerns.
Since the sample was procured anonymously by an independent individual, the risk of selective batch submission by the manufacturer or reseller is eliminated. Independent consumer-funded testing is one of the most reliable methods for evaluating product consistency.
While a slight underdosage may not present significant issues for most users, accurate dosing is crucial for maintaining predictable results. This emphasizes the need for strict quality control in manufacturing.
Conclusion
The analysis of HYB’s Testosterone Cypionate injectable reveals a minor underdosage of 4.4%, with a measured concentration of 286.80 mg/ml versus the 300 mg/ml label claim. While this confirms the presence of the declared active ingredient, the deviation highlights the importance of manufacturing consistency.
The anonymously procured nature of the sample strengthens the objectivity of this manufacturer-independent evaluation. Consumers are encouraged to refer to third-party testing before making purchasing decisions.
This report serves as an educational resource for harm reduction and informed consumer decision-making.
Disclaimer
This report is published for educational and harm reduction purposes. While individual consumer-funded testing provides valuable insight into product quality, continued independent verification across multiple batches remains essential. Readers are encouraged to interpret this information critically and use independent data for informed decision-making.
